• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Primary PCI versus Pharmaco-Invasive Strategy in Patients with ST-Elevation Myocardial Infarction; a Randomized Clinical Study
Conclusion: Immediate fibrinolysis followed by coronary angiography 3-24 hr later resulted in similar short term outcome and earlier effective reperfusion in patients with STEMI compared to PPCI.Keywords:Fibrinolysis,PCI,Reperfusion,STEMIView:PDF (323.13 KB)Click here to download the PDF file.‹ Probability of Dying and Survival Analysis of Diabetic and/Hypertensive Patients Who Undergone Hemodialysis with Heart Disease Complication: A Comparison between a Hemodialysis Center Jakarta, Indonesia and Penang, MalaysiaAssessment of Risk Factors for the Cardiovascular Diseases in People Visiting a Tertiary Care Hospital for Ro...
Source: Journal of Cardiovascular Disease Research - March 8, 2018 Category: Cardiology Authors: yunus Source Type: research